Literature DB >> 21692947

Hepatitis C virus replication in Caucasian HIV controllers.

E Ruiz-Mateos1, K Machmach, M C Romero-Sanchez, S Ferrando-Martinez, P Viciana, M Del Val, M A Muñoz-Fernandez, M Genebat, M Leal.   

Abstract

Whether HIV controllers, patients who spontaneously control HIV viraemia, are able to control hepatitis C virus (HCV) infection, in terms of spontaneous clearance or lower HCV replication, is not well understood. To assess to what extent Caucasian HIV controllers are able to control HCV replication and potential associated factors, plasma HIV-1 and HCV RNA levels, anti-HCV antibodies, HCV genotype and human leucocyte antigens (HLA) typing were determined in samples from 75 HIV controllers (33 viraemic controllers, <1000 HIV-1 RNA copies/mL, and 42 elite controllers, <40 HIV-1 RNA copies/mL) and compared with 261 HIV-infected noncontrollers. We did not find differences in the HCV spontaneous clearance rates between groups. However, we interestingly found a lower HCV viral load in HIV controllers, alongside a different distribution of HCV genotypes in relation to the comparison group. In addition, HLA-B57 was associated with a lower HCV viral load in the control group and HIV controllers, and conversely, HLA-B35 with higher HCV viral load in HIV controllers. The subrepresentation of HCV genotype 1 and the overrepresentation of HLA-B57 only partly explained the lower HCV viral load found in HIV controllers. In fact, HIV controller status was independently associated with lower HCV viral load, together with HCV genotype non-1, the presence of HLA-B57 and absence of HLA-B35. Caucasian HIV controllers are able to better control HCV replication, in terms of lower HCV viral load levels. These findings support the idea that some common host mechanisms are involved in the defence against these two persistent infections.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692947     DOI: 10.1111/j.1365-2893.2010.01431.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  15 in total

Review 1.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

2.  Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.

Authors:  Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

3.  A closer look at hepatitis C clearance in HIV controllers: a response.

Authors:  Alice K Asher; Glenn-Milo Santos; Jennifer Evans; E Kainne Dokubo; Tzong-Hae Lee; Jeffrey N Martin; Steven G Deeks; Leslie H Tobler; Michael Busch; Peter W Hunt; Kimbely Page
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

4.  HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.

Authors:  M Frías; D Rodríguez-Cano; F Cuenca-López; J Macías; A Gordon; B Manzanares-Martín; J A Pineda; Á Camacho; J Torre-Cisneros; J Peña; A Rivero-Juárez; A Rivero
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

5.  Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions.

Authors:  Joyce L Sanchez; Peter W Hunt; Cavan S Reilly; Hiroyu Hatano; Gregory J Beilman; Alexander Khoruts; Jake S Jasurda; Ma Somsouk; Ann Thorkelson; Samuel Russ; Jodi Anderson; Steven G Deeks; Timothy W Schacker
Journal:  J Infect Dis       Date:  2014-10-24       Impact factor: 5.226

6.  Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  M G Law; A Achhra; S G Deeks; B Gazzard; S A Migueles; R M Novak; M Ristola
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

7.  Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers.

Authors:  Alice K Asher; Glenn-Milo Santos; Jennifer Evans; Emily K Dokubo; Tzong-Hae Lee; Jeffrey N Martin; Steven G Deeks; Leslie H Tobler; Michael Busch; Peter W Hunt; Kimberly Page
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

8.  The interplay between the X-DING-CD4, IFN-α and IL-8 gene activity in quiescent and mitogen- or HIV-1-exposed PBMCs from HIV-1 elite controllers, AIDS progressors and HIV-negative controls.

Authors:  Rakhee Sachdeva; Rasheda Y Shilpi; Malgorzata Simm
Journal:  Innate Immun       Date:  2013-06-10       Impact factor: 2.680

9.  Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  AIDS Res Treat       Date:  2012-05-27

10.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.